Haemonetics (NYSE: HAE) buys Vivasure Medical for €100M plus up to €85M

Rhea-AI Filing Summary

Haemonetics Corporation has completed the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company developing next-generation technology for percutaneous vessel closure. Haemonetics acquired all outstanding equity interests of Vivasure for €100 million, or approximately €52 million net of certain prior investments, loans and other customary closing adjustments. The agreement also includes up to an additional €85 million in contingent consideration tied to sales growth and other milestones, subject to adjustment for specified prior investments and loan amounts. Haemonetics financed the transaction entirely with available cash on hand.

Insights

Healthcare M&A analyst

Haemonetics deploys cash to buy Vivasure for €100M plus earnout.

Haemonetics Corporation has acquired all equity of Vivasure Medical Limited for €100 million, with net consideration of approximately €52 million after accounting for prior investments, loans and customary closing adjustments. Vivasure focuses on next-generation technology for percutaneous vessel closure, which sits within the vascular access and cardiovascular procedure ecosystem.

The structure includes up to an additional €85 million of contingent consideration linked to sales growth and specified milestones, with further adjustment tied to prior investments and loan amounts. This mix of upfront and milestone-based payments spreads the purchase cost over time based on Vivasure’s commercial performance.

The transaction is funded from Haemonetics’ cash on hand, so there is no disclosed new financing or equity issuance tied to this deal in the provided content. Future disclosures in company filings may provide more detail on integration progress and the financial contribution of Vivasure’s vessel closure technology.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000313143false00003131432026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $.01 par value per share			HAE			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 9, 2026, Haemonetics Corporation (the “Company”) announced its acquisition of Vivasure Medical Limited (“Vivasure”), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Under the terms of the definitive agreement between the parties, the Company acquired all of the outstanding equity interests of Vivasure for €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by the Company to Vivasure as well as other customary closing adjustments, and up to an additional €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. The Company financed this transaction through available cash on hand.

A copy of the Company’s press release announcing the transaction is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release issued by Haemonetics Corporation on January 9, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

January 9, 2026

By:

/s/ Christopher A. Simon

Name:

Christopher A. Simon

Title:

President and Chief Executive Officer

FAQ

What acquisition did Haemonetics (HAE) announce on January 9, 2026?

Haemonetics Corporation announced that it acquired all outstanding equity interests of Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation percutaneous vessel closure technology.

How much did Haemonetics (HAE) pay to acquire Vivasure Medical?

Haemonetics agreed to acquire Vivasure for €100 million, or approximately €52 million net of certain prior investments, loans and customary closing adjustments, plus up to an additional €85 million in contingent consideration.

How is the additional contingent consideration for the Vivasure deal structured for Haemonetics (HAE)?

The agreement provides for up to an additional €85 million in contingent consideration based on sales growth and achievement of certain other milestones, with amounts also subject to adjustment for specified prior investments and loan values.

How did Haemonetics (HAE) finance the acquisition of Vivasure Medical?

Haemonetics financed the Vivasure acquisition using its available cash on hand, with no additional financing arrangements described in the provided content.

What type of technology does Vivasure Medical bring to Haemonetics (HAE)?

Vivasure Medical is described as pioneering next-generation technology for percutaneous vessel closure, which is used to close blood vessels after certain minimally invasive procedures.

Is there a press release related to Haemonetics’ (HAE) Vivasure acquisition?

Yes. A press release announcing the transaction is furnished as Exhibit 99.1, and it is specifically stated that this press release is furnished and not filed for purposes of certain Exchange Act liabilities.